The EXHALE 1A Study
Research type
Research Study
Full title
A cross-sectional study to explore the relationship between the level of Exhlaed Breath Condensate Hydrogen Peroxide (EBC H2O2) as measured using a new device (Inflammacheck) against exisiting measurements of lung disease and inflammation in patients with asthma and COPD, and healthy volunteers, The EXHALE 1A study
IRAS ID
195574
Contact name
Anoop Chauhan
Contact email
Sponsor organisation
Portsmouth Hospitals NHS Trust
Duration of Study in the UK
1 years, 7 months, 26 days
Research summary
Asthma and Chronic Obstructive Pulmonary Disease (COPD) are common lung conditions that affect over 6 million people in the UK. There are still many people who remain undiagnosed and suffer as a result. Attacks (or 'exacerbations') of asthma and COPD can be difficult to detect and treat quickly, resulting in frequent hospital admissions.
We know airway inflammation is a feature of asthma and COPD and can be used to help diagnose these conditions. Current ways of assessing airway inflammation can be invasive or difficult for patients to complete. ‘Inflammacheck’ is a novel, non-invasive breathing test that collects exhaled breath condensate hydrogen peroxide. The air we breathe out (‘exhaled breath’) contains particles from the fluid lining our airways. These include substances that have been produced by inflammation within our lungs: one of these chemicals is hydrogen peroxide (H2O2). By detecting hydrogen peroxide ‘Inflammacheck’ gives a direct measure of airway inflammation.
We need to study 'Inflammacheck' in asthmatic and COPD patients, to see if it can detect airway inflammation in these patients compared to people without lung disease.The Study:
Will be performed at Queen Alexandra Hospital (QAH), Portsmouth. We will recruit 50 patients with asthma, 50 with COPD and 50 healthy controls. People will be recruited from QAH outpatient clinics. Once consented, participants will have; baseline information taken, complete questionnaires about their disease, perform standard breathing tests including the new 'Inflammacheck' test and have a sample of blood taken. 'Inflammacheck' is designed so that it requires a person to simply breathe into a mouthpiece at their normal, relaxed rate of breathing for 60 seconds. Once completed, participants will fill in a questionnaire about their experience of the new ‘Inflammacheck’ device.REC name
South Central - Berkshire Research Ethics Committee
REC reference
17/SC/0626
Date of REC Opinion
31 Jan 2018
REC opinion
Further Information Favourable Opinion